Description of Invention: The following biological material is a hybridoma cell line generated from mice lymphocytes immunized with human mammary carcinomas and fused to a myeloma cell line. The resulting mouse monoclonal antibody (MAb, clone B1.1) is directed against carcinoembryonic antigen (CEA). CEA are glyco-proteins whose expression levels are increased on the surface of metastatic cancer cells. Therefore, antibodies generated from the hybridoma clone B1.1 can be used to detect cancer cells. MAb B1.1 binds to the surface of human breast and melanoma cell lines and cells associated with colon carcinomas and adenomas. The antibody has been tested to work effectively in several techniques such as Immunofluoresence, Western Blot, Fluorescent Activated Cell Sorting (FACS), and Immunohistochemistry (IHC).
Developing cancer biomarker
Developing cell sorting assays (e.g. FACS)
Immunofluoresence, Western Blotting, and Immunohistochemistry for CEA
Developing prognostic assays for cancer
Advantages: Tested to bind CEA and can be used in different Immunological Techniques such as Immunofluoresence, Western Blot, Fluorescent Activated Cell Sorting (FACS), and Immunohistochemistry (IHC).
Inventors: No Inventor Information Available.
Patent Status: Research Material. Patent protection is not being pursued for this technology.
Licensing Status: Materials Available: 1 vial of Hybridoma cell line (B1.1). Available for licensing under a Biological Materials License Agreement.